Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H11ClF3N5O4 |
| Molecular Weight | 441.749 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(=O)NN(CN2C=CC(=C(OC3=CC(=CC(Cl)=C3)C#N)C2=O)C(F)(F)F)C1=O
InChI
InChIKey=ASRRTCGVOYDHBZ-UHFFFAOYSA-N
InChI=1S/C17H11ClF3N5O4/c1-24-15(28)23-26(16(24)29)8-25-3-2-12(17(19,20)21)13(14(25)27)30-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,23,28)
| Molecular Formula | C17H11ClF3N5O4 |
| Molecular Weight | 441.749 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:02:41 GMT 2023
by
admin
on
Sat Dec 16 15:02:41 GMT 2023
|
| Record UNII |
68YY6J2MH4
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
68YY6J2MH4
Created by
admin on Sat Dec 16 15:02:41 GMT 2023 , Edited by admin on Sat Dec 16 15:02:41 GMT 2023
|
PRIMARY | |||
|
156613627
Created by
admin on Sat Dec 16 15:02:41 GMT 2023 , Edited by admin on Sat Dec 16 15:02:41 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
M9 is the primary metabolite resulting from DOR via CYP3A metabolism in humans. Co-administration of rifabutin (a CYP3A inducer) with DOR, may result in increased M9 exposure.
MAJOR
|
